Haisco Pharmaceutical Group - Haisco's independently developed pre-clinical autoimmune innovation drug has received an exclusive overseas license, with potential value exceeding $1.5 billion.

CN EN

Stock code: 002653.SZ

Home

News

Innovation

Pipeline R&D Platforms

Products

Product List Product Topics Pharmacovigilance

Investors

Stock Information Company Announcements Market Data Q&A Investor Hotline

Join Us

Talent Philosophy Careers

About Haisco

About Us Business Presence

GLOBAL

English China

Back

Haisco's independently developed pre-clinical autoimmune innovation drug has received an exclusive overseas license, with potential value exceeding $1.5 billion.

On August 25, Haiscoo announced a global exclusive licensing agreement with US company Sentivera Therapeutics. Sentivera will receive exclusive rights to develop, produce, and commercialize a pre-clinical autoimmune project worldwide, except in the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan Region.

Sentivera will pay Heisike approximately $75.89 million as a down payment (including $40 million in cash and an equivalent $35.89 million worth of 17.5% equity in Sentivera), along with additional milestone payments of up to $1.46 billion and a tiered royalty rate of up to 10%. If Sentivera reaches a re-licensing agreement for the project, Heisike also has the right to receive revenue shares from the re-licensing income.

This project is a oral small-molecule formulation independently developed by Hisico, with independent intellectual property rights. It is intended for the treatment of inflammatory diseases. Pre-clinical research data indicate that this project demonstrates significant pharmacological activity in related animal models, and its mechanism of action is clear. Based on the current results, this project has clear development value and good translational prospects, and is expected to provide clinical patients with a efficient and safe new treatment option. Currently, this project has been approved for clinical trials in China.

The signing of this agreement will further accelerate the development and commercialization of the project on a global scale. This move is in line with the company’s overall development strategy of internationalization and innovation-driven growth, and represents an important step in deepening the global presence and accelerating the transformation of innovative outcomes.

About Sentivera

Sentivera is a company established in Delaware, USA on November 25, 2025, and is founded and supported by Population Health Partners, L.P.

Key investors:

Population Health Partners, L.P.（“PHP”）

PHP is an investment and enterprise incubation institution focused on the field of life sciences. It aims to address the health and economic challenges posed by common diseases and extend human health lifespan. PHP combines rigorous capital management with extensive scientific research, clinical development, and business operations experience. Its goal is to identify treatment opportunities with significant impact and establish and develop companies around these opportunities, thereby efficiently advancing the development of innovative drugs. The ultimate objective is to achieve a health impact that benefits a wide range of people, while providing attractive risk-adjusted returns for investors.

ARCH Venture Partners（ARCH）

ARCH is an early investment firm focused on establishing and investing in biotech and technology platform companies with groundbreaking potential. The company is widely recognized for creating world-leading enterprises and is committed to combining innovative approaches driven by science with exceptional management teams. Over the past four decades, ARCH has consistently worked to promote disruptive innovation and develop solutions that can transform human life, bringing revolutionary changes to the fields of healthcare and cutting-edge technology.

About Haisco

Hisicor is an international pharmaceutical company integrating research and development, production, and sales (stock code 002653.SZ). It focuses on areas such as anesthesia and analgesia, chronic disease metabolism, digestive liver diseases, respiratory autoimmune diseases, the nervous system, and tumors. Adhering to innovation and globalization strategies, with the vision of “becoming the most trusted international pharmaceutical company,” Hisicor aims to meet unmet clinical needs and care for patients worldwide. Currently, Hisicor Pharmaceutical Group has established a range of diversified research and development programs with independent intellectual property rights, covering small molecule innovative drugs, biopharmaceuticals, and high-end generic drugs. Many projects are in the clinical development stage, and several innovative drugs have been commercialized, providing diverse innovative product solutions to the world.

Business News